Business
AGM Statement
AGM Statement.
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\n27 June 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\n \nAGM statement and strategic update\nSolvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, announces that all resolutions proposed at its Annual General Meeting (\"AGM\") held earlier today were duly passed. A summary of the resolutions is provided at the end of this announcement.\nThis year's AGM marks a significant milestone in the Company's growth trajectory. Following the successful completion of the acquisition of Awakn Life Sciences on 28 May 2025, Solvonis has rapidly established itself as a leading European innovator in the development of precision neuropsychiatric therapeutics.\nThe combined company now benefits from a high-quality pipeline of preclinical and clinical-stage assets targeting alcohol use disorder, post-traumatic stress disorder, and other complex neuropsychiatric conditions. These programmes, including lead candidate SVN-001, are underpinned by translational science, real-world evidence, and a regulatory strategy aligned with expedited pathways in key jurisdictions.\nIntegration activities are progressing in line with plan, with a focus on operational efficiency, disciplined capital deployment, and preparing lead programmes for Phase 3 readiness and partnering opportunities. Solvonis continues to advance a virtual biotech model, supported by a lean team and an expanding network of expert collaborators and CROs.\nAnthony Tennyson, CEO of Solvonis Therapeutics, commented: \"Today's AGM reflects strong shareholder support for our vision and execution. With the acquisition of Awakn now complete, we are strategically positioned to lead in transforming the treatment landscape for substance use and treatment-resistant mental health disorders across Europe and beyond. We are focused on delivering value through rigorous development, targeted commercial strategy, and partnerships that extend our reach and impact.\"\nThe Board remains committed to building a capital-efficient, data-driven, and licensing-led business capable of delivering meaningful therapeutic advances and long-term value creation.\nFurther updates on programme progress and strategic initiatives will be provided in due course.\nAs noted, all resolutions proposed at th...